Prenatal opioid use is associated with increased maternal and infant mortality, prematurity, and poor neonatal outcomes.
Our data regarding prenatal exposure to BZDs and/or z-drugs and risk of neurodevelopmental outcomes is still sparse.
The PLLR helps to put the potential effects of the drug into perspective with the goal of providing a more individualized risk-benefit analysis.
Many women experience depression during pregnancy. What is the best way to identify these women?
There are many different sources of information, some better than others.
This article reviews the research on the effects of antenatal maternal psychological states on offspring.
More study is needed regarding the safety of sedative-hypnotic medications during pregnancy.
While questions and controversies remain, the information on long-term neurodevelopmental outcomes in children prenatally exposed to antidepressants is largely reassuring.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.
